m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT00632
 [1], [2], [3], [4], [5], [6], [7]
m6A modification hsa-mir-146a hsa-mir-146a METTL14 Methylation : m6A sites Indirect Inhibition RNA modification MALAT1 MALAT1 FTO Demethylation : modification sites
m6A Modification:
m6A Regulator Methyltransferase-like 14 (METTL14) WRITER
 Regulator Info 
m6A Target hsa-mir-146a
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type RNA modification (RNAMod)  >> N6,2'-O-dimethyladenosine (m6Am)
Epigenetic Regulator Fat mass and obesity-associated protein (FTO) ERASER View Details
Regulated Target Metastasis associated lung adenocarcinoma transcript 1 (MALAT1) View Details
Crosstalk Relationship m6Am  →  m6A Inhibition
Crosstalk Mechanism RNA modification indirectly impacts m6A modification through downstream signaling pathways
Crosstalk Summary FTO interacts with Metastasis associated lung adenocarcinoma transcript 1 (MALAT1), decreasing it's m6Am level and inhibiting its physical interaction with hsa-mir-146a, which was regulated by METTL14-mediated m6A modification.
In-vitro Model
 253J Bladder carcinoma Homo sapiens CVCL_7935
HT-1197 Recurrent bladder carcinoma Homo sapiens CVCL_1291
HT-1376 Bladder carcinoma Homo sapiens CVCL_1292
MDA-MB-231 Breast adenocarcinoma Homo sapiens CVCL_0062
MCF-7 Invasive breast carcinoma Homo sapiens CVCL_0031
References
Ref 1 FTO modifies the m6A level of MALAT and promotes bladder cancer progression. Clin Transl Med. 2021 Feb;11(2):e310. doi: 10.1002/ctm2.310.
Ref 2 The tumor-suppressive effects of alpha-ketoglutarate-dependent dioxygenase FTO via N6-methyladenosine RNA methylation on bladder cancer patients. Bioengineered. 2021 Dec;12(1):5323-5333. doi: 10.1080/21655979.2021.1964893.
Ref 3 METTL14 promotes the migration and invasion of breast cancer cells by modulating N6?methyladenosine and hsa?miR?146a?5p expression. Oncol Rep. 2020 May;43(5):1375-1386. doi: 10.3892/or.2020.7515. Epub 2020 Feb 24.
Ref 4 Long noncoding RNA MALAT1 inhibits the apoptosis and autophagy of hepatocellular carcinoma cell by targeting the microRNA-146a/PI3K/Akt/mTOR axis. Cancer Cell Int. 2020 May 13;20:165. doi: 10.1186/s12935-020-01231-w. eCollection 2020.
Ref 5 MALAT1 modulates miR-146's protection of microvascular endothelial cells against LPS-induced NF-kappaB activation and inflammatory injury. Innate Immun. 2019 Oct;25(7):433-443. doi: 10.1177/1753425919861427. Epub 2019 Jul 10.
Ref 6 Targeting MALAT1 induces DNA damage and sensitize non-small cell lung cancer cells to cisplatin by repressing BRCA1. Cancer Chemother Pharmacol. 2020 Nov;86(5):663-672. doi: 10.1007/s00280-020-04152-7. Epub 2020 Oct 8.
Ref 7 Long non-coding RNA MALAT1 modulate cell migration, proliferation and apoptosis by sponging microRNA-146a to regulate CXCR4 expression in acute myeloid leukemia. Hematology. 2021 Dec;26(1):43-52. doi: 10.1080/16078454.2020.1867781.